Merck and Mayo Clinic have launched a research collaboration to use artificial intelligence (AI) and large-scale clinical data to accelerate drug discovery and development, with an initial focus on diseases with high unmet needs, including multiple sclerosis (MS). The partnership will combine Mayo’s extensive clinical and genomic datasets with Merck’s AI-enabled research technologies. The Merck […]
The post M&M: Merck, Mayo Clinic team up to use AI to speed drug development in MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com